

PATENT

Attorney Docket No. UCSD-07017

**AMENDMENTS TO THE CLAIMS
PURSUANT TO REVISED 37 CFR § 1.21**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

1. (Currently Amended) A ~~universal~~ vaccine for treating tumors of any origin, comprising: at least one telomerase reverse transcriptase(~~hTERT~~) (TRT) peptide in an amount effective for initiating and enhancing a cytotoxic T lymphocyte (CTL) response against mammalian ~~cancer~~ cells; ~~[[and]]~~a physiologically acceptable carrier; and a helper peptide.
2. (Currently Amended) The vaccine according to claim 1, wherein the telomerase peptide is modified to enhance binding to a major histocompatibility complex (~~AMC~~)(MHC) molecule.
3. (Currently Amended) The vaccine according to claim 2, wherein the MHC molecule is a Class I MHC molecule.
4. (Currently Amended) The vaccine according to claim 3, wherein the ~~MHC~~MHC molecule is a human leucocyte antigen (HLA).
5. (Original) The vaccine according to claim 4, wherein the MHC molecule is HLA-A2~~HLA-2.~~
6. (Currently Amended) The vaccine according to claim 1, wherein the ~~[[h]]~~TRT peptide is a human telomerase reverse transcriptase peptide.
7. (Original) The vaccine according to claim 6, wherein the peptide is from about 7 to about 15 amino acid residues in length.
8. (Original) The vaccine according to claim 1, wherein the peptide is effective alone.

PATENTAttorney Docket No. UCSD-~~0701~~7

9. (Withdrawn) The vaccine according to claim 1, wherein the peptide is effective in combination with other peptides.
10. (Original) The vaccine according to claim 1, wherein the vaccine also comprises an adjuvant.
11. (Withdrawn) The vaccine according to claim 1, wherein the carrier is a mammalian cell.
12. (Withdrawn) The vaccine according to claim 11, wherein the carrier mammalian cell is a transfected or transgenic cell.
13. (Withdrawn) A synthetic hTRT peptide restricted by a Class I major histocompatibility complex (MHC) molecule.
14. (Withdrawn) A method for inducing and enhancing a CTL response against cancer cells, comprising: harvesting mammalian blood leucocytes; pulsing with an effective amount of hTRT; and contacting cancer cells with an effective amount of pulsed leucocytes.
15. (Withdrawn) The method according to claim 13, wherein the contacting is accomplished *in vitro*.
16. (Withdrawn) The method according to claim 13, wherein the contacting is accomplished *in vivo*.
17. (Withdrawn) A method for targeting cytotoxic lymphocytes (CTL) to tumor cells by administering an effective amount of telomerase transcriptase (TRT) peptide to a mammalian recipient, which amount is effective to attract CTL to the tumor cells.
18. (Withdrawn) The method according to claim 16, wherein the recipient is a cancer patient.

PATENT

Attorney Docket No. UCSD-07017

19. (New) A composition for induction of a cytotoxic T lymphocyte response, comprising: at least one HLA-A2-restricted telomerase reverse transcriptase (TRT) peptide in an amount effective for initiating and enhancing a cytotoxic T lymphocyte (CTL) response against an HLA-A2 positive target cell; and a physiologically acceptable carrier.
20. (New) The composition of claim 19, wherein said HLA-A2 is HLA-A2.1.
21. (New) The composition of claim 19, wherein said at least one TRT peptide comprises a peptide with a sequence set forth as SEQ ID NO:1.
22. (New) The composition of claim 19, wherein said at least one TRT peptide comprises a peptide with a sequence set forth as SEQ ID NO:2.
23. (New) The composition of Claim 19, wherein said at least one TRT peptide comprises a first peptide with a sequence set forth as SEQ ID NO:1, and a second peptide with a sequence set forth as SEQ ID NO:2.
24. (New) The composition of Claim 19, further comprising a helper peptide.